Codexis, Inc. (CDXS)

Price$2.59

Favorite Metrics

Price vs S&P 500 (26W)-8.75%

Price vs S&P 500 (4W)52.38%

Market Capitalization$235.35M

All Metrics

Book Value / Share (Quarterly)$0.56

P/TBV (Annual)9.72x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-20.22%

Cash Flow / Share (Quarterly)$-0.26

Price vs S&P 500 (YTD)54.76%

Gross Margin (TTM)86.73%

Net Profit Margin (TTM)-62.47%

EPS (TTM)$-0.52

10-Day Avg Trading Volume1.67M

EPS Excl Extra (TTM)$-0.52

Revenue Growth (5Y)0.37%

EPS (Annual)$-0.50

ROI (Annual)-48.52%

Gross Margin (Annual)86.73%

Net Profit Margin (5Y Avg)-65.14%

Cash / Share (Quarterly)$0.86

Revenue Growth QoQ (YoY)81.34%

ROA (Last FY)-29.75%

Revenue Growth TTM (YoY)18.61%

EBITD / Share (TTM)$-0.48

ROE (5Y Avg)-61.75%

Operating Margin (TTM)-59.30%

Cash Flow / Share (Annual)$-0.26

P/B Ratio4.66x

P/B Ratio (Quarterly)2.91x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)3.19x

Net Interest Coverage (TTM)-137.00x

ROA (TTM)-32.64%

EV / EBITDA (TTM)440.52x

EPS Incl Extra (Annual)$-0.50

Current Ratio (Annual)3.82x

Quick Ratio (Quarterly)3.53x

3-Month Avg Trading Volume1.92M

52-Week Price Return22.17%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.74

P/S Ratio (Annual)3.34x

Asset Turnover (Annual)0.48x

52-Week High$3.87

Operating Margin (5Y Avg)-62.68%

EPS Excl Extra (Annual)$-0.50

CapEx CAGR (5Y)3.58%

Tangible BV CAGR (5Y)-26.04%

26-Week Price Return0.00%

Quick Ratio (Annual)3.53x

13-Week Price Return45.51%

Total Debt / Equity (Annual)0.79x

Current Ratio (Quarterly)3.82x

Enterprise Value$224.664

Revenue / Share Growth (5Y)-7.04%

Asset Turnover (TTM)0.52x

Book Value / Share Growth (5Y)-26.73%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)5.16x

Pretax Margin (Annual)-62.41%

Cash / Share (Annual)$0.86

3-Month Return Std Dev115.69%

Gross Margin (5Y Avg)78.46%

Net Income / Employee (TTM)$-0

ROE (Last FY)-87.03%

EPS Basic Excl Extra (Annual)$-0.50

P/FCF (TTM)12.02x

Receivables Turnover (TTM)4.76x

Total Debt / Equity (Quarterly)0.79x

EPS Incl Extra (TTM)$-0.52

Receivables Turnover (Annual)4.76x

ROI (TTM)-51.32%

P/S Ratio (TTM)3.34x

Pretax Margin (5Y Avg)-65.02%

Revenue / Share (Annual)$0.81

Tangible BV / Share (Annual)$0.46

Price vs S&P 500 (52W)-12.93%

Year-to-Date Return58.90%

5-Day Price Return12.61%

EPS Normalized (Annual)$-0.50

ROA (5Y Avg)-30.29%

Net Profit Margin (Annual)-62.47%

Month-to-Date Return58.90%

Cash Flow / Share (TTM)$-1.13

EBITD / Share (Annual)$-0.48

Operating Margin (Annual)-59.30%

LT Debt / Equity (Annual)0.79x

ROI (5Y Avg)-48.16%

LT Debt / Equity (Quarterly)0.79x

EPS Basic Excl Extra (TTM)$-0.52

P/TBV (Quarterly)8.55x

P/B Ratio (Annual)2.91x

Inventory Turnover (TTM)5.16x

Pretax Margin (TTM)-62.41%

Book Value / Share (Annual)$0.56

Price vs S&P 500 (13W)42.64%

Beta2.39x

P/FCF (Annual)79.24x

Revenue / Share (TTM)$0.78

ROE (TTM)-90.51%

52-Week Low$0.96

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.08

Industry Peers — Industrial Chemicals(20)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CDXSCodexis, Inc.	3.34x	18.61%	86.73%	—	$2.59
LYBLyondellBasell Industries N.V. Class A	0.71x	-25.18%	8.55%	-15.31%	$66.27
IFFInternational Flavors & Fragrances Inc.	1.78x	-5.17%	36.16%	—	$75.88
WLKWestlake Corporation	1.31x	-8.01%	7.28%	7.35%	$112.61
MEOHMethanex Corp	1.26x	-3.51%	25.33%	16.22%	$54.13
NEUNewMarket Corporation	2.19x	-2.20%	31.46%	12.64%	$634.39
SXTSensient Technology Corporation	2.65x	3.52%	33.92%	4.05%	$100.26
REXREX American Resources Corp.	2.18x	1.24%	14.41%	72.78%	$43.05
BAKBraskem S.A. American Depositary Shares (Each representing Two Class A Preferred Shares)	0.09x	-31.09%	2.66%	—	$3.57
GPREGreen Plains, Inc.	0.49x	-14.93%	6.69%	—	$14.82
WLKPWESTLAKE CHEMICAL PARTNERS LP	0.67x	2.71%	29.81%	-5.98%	$22.39

About

Codexis develops proprietary enzymatic solutions for biopharmaceutical and diagnostics manufacturing using its CodeEvolver technology platform. The company's enzymes improve production efficiency through higher yields and reduced energy consumption while enabling scaled manufacturing of RNAi therapeutics via its ECO Synthesis platform. Applications span small molecule pharmaceuticals, nucleic acid synthesis, and genomic diagnostics, with primary revenue generation from the Americas.